Top Stem Cell Stocks

In March of last year, President Barack Obama signed an executive order to eliminate a ban on federal funding for embryonic stem-cell research. This policy change should cause a substantial increase in research into stem cell therapy. Research has been continuing to utilize stem cells for gene therapy and the treatment of Parkinson’s disease, heart disease, diabetes, multiple sclerosis, arthritis, and many other medical conditions.

Stem cells can come from various sources including embryos, cord blood, which is the blood from umbilical cords, and even in baby teeth. WallStreetNewsNetwork.com just came up with a downloadable list of over ten stem cell stocks. Maybe one of these will provide a cure for your portfolio.

Alexion Pharmaceuticals (ALXN) is a Connecticut based company with a $4.7 billion market cap that is involved in the development of biologic therapeutic products for the treatment of hematologic and cardiovascular disorders, auto-immune diseases, and cancer. The stock has a PE of 15.9 and a forward PE of 21.6.

Cellgene (CELG) is a $24.3 billion market cap company involved in the discovery and production, of therapies designed to treat cancer and immune-inflammatory-related diseases. One of their main products is Thalomid, which is used for the treatment of erythema nodosum leprosum, a complication of leprosy. They also received patent on placental stem cell recovery. The stock sports a PE of 29 and a forward PE of 16.5.

Integra Lifesciences Holdings (IART) is a New Jersey based $1 billion market cap company that develops, manufactures, and sells medical devices, implants, biomaterials, and instruments to the stem cell, surgery, and soft tissue repair markets. Their P/E is 17.8, and the forward PE is 11.5.

For an Excel database of over ten stem cell stocks which you can download, sort, and change, go to WallStreetNewsNetwork.com.

Author does not own any of the above.

By Stockerblog.com